{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:08:36Z","timestamp":1790842116950,"version":"4.1.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2018,11,8]],"date-time":"2018-11-08T00:00:00Z","timestamp":1541635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UG1CA189823"],"award-info":[{"award-number":["UG1CA189823"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U10CA180790"],"award-info":[{"award-number":["U10CA180790"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U10CA180791"],"award-info":[{"award-number":["U10CA180791"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U10CA180838"],"award-info":[{"award-number":["U10CA180838"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U10CA180850"],"award-info":[{"award-number":["U10CA180850"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U10CA180857"],"award-info":[{"award-number":["U10CA180857"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U10CA180867"],"award-info":[{"award-number":["U10CA180867"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UG1CA189819"],"award-info":[{"award-number":["UG1CA189819"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UG1CA189850"],"award-info":[{"award-number":["UG1CA189850"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>A few previous studies report a direct relationship between older age and chemotherapy-induced neuropathy. This study further evaluated this adverse event's age-based risk.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>CALGB 40101 investigated adjuvant paclitaxel (80 mg\/m2 once per week or 175 mg\/m2 every 2 weeks) in patients with breast cancer and served as a platform for the current study that investigated age-based differences in neuropathy. Grade 2 or worse neuropathy, as per Common Terminology Criteria for Adverse Events version 4, was the primary endpoint; patients were assessed at baseline, every 6 months for 2 years, and then annually for 15 years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among these 1,881 patients, 230 were 65 years of age or older, 556 were 55\u201364 years, and 1,095 were younger than 55; 1,226 neuropathy events (commonly grade 1 or 2) were reported in 65% of the cohort. The number of grade 2 or worse events was 63 (27%), 155 (28%), and 266 (24%) within respective age groups (p = .14). In univariate analysis, only motor neuropathy had a higher age-based incidence: 19 (8%), 43 (8%), and 60 (5%), respectively (p = .04); in multivariate analyses, this association was no longer statistically significant. Other endpoints, such as time to onset of neuropathy (time from trial enrollment to neuropathy development) and time to improvement (time from maximal grade sensory neuropathy to a one-category improvement), showed no statistically significant age-based differences. In contrast, obesity was associated with neuropathy, and every 2-week paclitaxel was associated with trends toward neuropathy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Although paclitaxel-induced neuropathy is common, older age is not an independent risk factor. Clinical trial identification number. NCT00041119 (CALGB 40101).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2018-0298","type":"journal-article","created":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T12:07:38Z","timestamp":1541765258000},"page":"617-623","source":"Crossref","is-referenced-by-count":30,"title":["Age and the Risk of Paclitaxel-Induced Neuropathy in Women with Early-Stage Breast Cancer (Alliance A151411): Results from 1,881 Patients from Cancer and Leukemia Group B (CALGB) 40101"],"prefix":"10.1093","volume":"24","author":[{"given":"Myra","family":"Barginear","sequence":"first","affiliation":[{"name":"Northwell Health Cancer Institute, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amylou C.","family":"Dueck","sequence":"additional","affiliation":[{"name":"Department of Health Sciences Research, Mayo Clinic, Scottsdale, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob B.","family":"Allred","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Bunnell","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Partners CancerCare, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey J.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Center for the Study of Aging and Human Development and, Duke University Medical Center, Durham, North Carolina, USA"},{"name":"Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel A.","family":"Freedman","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Partners CancerCare, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arti","family":"Hurria","sequence":"additional","affiliation":[{"name":"City of Hope, Duarte, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gretchen","family":"Kimmick","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer G.","family":"Le-Rademacher","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota, USA"},{"name":"Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Lichtman","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, Commack, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyman B.","family":"Muss","sequence":"additional","affiliation":[{"name":"University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence N.","family":"Shulman","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Sitiki","family":"Copur","sequence":"additional","affiliation":[{"name":"Saint Francis Cancer Treatment Center, University of Nebraska Medical Center, Omaha, Nebraska, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Biggs","sequence":"additional","affiliation":[{"name":"Christiana Care Health System-Christiana Hospital, Newark, Delaware, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhuvaneswari","family":"Ramaswamy","sequence":"additional","affiliation":[{"name":"Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline M.","family":"Lafky","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aminah","family":"Jatoi","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,11,8]]},"reference":[{"key":"2021122506422059400_R1","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/annonc\/mdr297","article-title":"Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: Combined analysis of CALGB 9342 and 9840","volume":"23","author":"Lichtman","year":"2012","journal-title":"Ann Oncol"},{"key":"2021122506422059400_R2","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1200\/JCO.2015.66.2346","article-title":"Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in Southwest Oncology Group clinical trials","volume":"34","author":"Hershman","year":"2016","journal-title":"J Clin Oncol"},{"key":"2021122506422059400_R3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00520-005-0868-6","article-title":"Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy?","volume":"14","author":"Argyriou","year":"2006","journal-title":"Support Care Cancer"},{"key":"2021122506422059400_R4","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/cncr.11548","article-title":"The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel","volume":"98","author":"Hensing","year":"2003","journal-title":"Cancer"},{"key":"2021122506422059400_R5","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jgo.2012.04.002","article-title":"Is age \u2265 70 years an important predictor of adverse events among patients enrolled in metastastic melanoma trials? Findings from pooled analyses of therapeutic trials","volume":"3","author":"Jatoi","year":"2012","journal-title":"J Geriatric Oncol"},{"key":"2021122506422059400_R6","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.cllc.2015.02.006","article-title":"Treatment of elderly patients with non-small cell lung cancer: Results of an international expert panel meeting of the Italian Association of Thoracic Oncology","volume":"16","author":"Gridelli","year":"2015","journal-title":"Clin Lung Cancer"},{"key":"2021122506422059400_R7","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1634\/theoncologist.2012-0155","article-title":"Doublet chemotherapy in the elderly patient with ovarian cancer","volume":"17","author":"Teo","year":"2012","journal-title":"The Oncologist"},{"key":"2021122506422059400_R8","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1200\/JCO.2013.53.7142","article-title":"Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0-3 positive lymph nodes: CALGB 40101 (Alliance)","volume":"32","author":"Shulman","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021122506422059400_R9","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1200\/JCO.2011.40.6405","article-title":"Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles of adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101","volume":"30","author":"Shulman","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122506422059400_R10","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1525-1438.2007.00794.x","article-title":"Validation and reduction of FACT\/GOG-Ntx subscale for platinum\/paclitaxel-induced neurologic symptoms: A Gynecological Oncology Group study","volume":"17","author":"Huang","year":"2007","journal-title":"Int J Gynecol Cancer"},{"key":"2021122506422059400_R11","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.6004\/jnccn.2015.0177","article-title":"Making the grade: The impact of low-grade toxicities on patient preference for treatment with novel agents","volume":"13","author":"Castellanos","year":"2015","journal-title":"J Natl Compr Cancer Netw"},{"key":"2021122506422059400_R12","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1200\/JCO.2015.63.3529","article-title":"Acute toxicity and quality of life after dose-intensified salvage radiation therapy for biochemically recurrent prostate cancer after prostatectomy: First results of the randomized trial SAKK 09\/10","volume":"33","author":"Ghadjar","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122506422059400_R13","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1200\/JCO.2013.52.0536","article-title":"Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB\/Alliance)","volume":"32","author":"Loprinzi","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021122506422059400_R14","article-title":"BMI, lifestyle factors and taxane-induced neuropathy in breast cancer patients: The Pathways Study","volume":"109","author":"Greenlee","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"2021122506422059400_R15","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s10549-016-3939-0","article-title":"Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: Prevalence, risk factors, and fall risk","volume":"159","author":"Bao","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"2021122506422059400_R16","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1634\/theoncologist.2010-0248","article-title":"Long-term neuropathy after oxaliplatin treatment: Challenging the dictum of reversibility","volume":"16","author":"Park","year":"2011","journal-title":"The Oncologist"},{"key":"2021122506422059400_R17","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1200\/JCO.2005.03.9289","article-title":"Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762)","volume":"24","author":"Lichtman","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122506422059400_R18","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/cncr.2820710216","article-title":"Age does not influence taxol dose intensity in recurrent carcinoma of the ovary","volume":"71","author":"Bicher","year":"1993","journal-title":"Cancer"},{"key":"2021122506422059400_R19","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0959-8049(02)00611-1","article-title":"Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer","volume":"39","author":"Smoreburg","year":"2003","journal-title":"Eur J Cancer"},{"key":"2021122506422059400_R20","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/cncr.27744","article-title":"Recommendations for including multiple symptoms as endpoints in cancer clinical trials: A report from the ASCPRO (Assessing the Symptoms of Cancer Using Patient-Reported Outcomes) Multisystem Task Force","volume":"119","author":"Cleeland","year":"2013","journal-title":"Cancer"},{"key":"2021122506422059400_R21","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1007\/s00520-016-3297-9","article-title":"The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): A systemic review","volume":"24","author":"Atkinson","year":"2016","journal-title":"Supportive Care in Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2018-0298","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2018-0298","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/5\/617\/41920951\/oncolo_24_5_617.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/5\/617\/41920951\/oncolo_24_5_617.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T06:43:05Z","timestamp":1640414585000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/24\/5\/617\/6439143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,8]]},"references-count":21,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,11,8]]},"published-print":{"date-parts":[[2019,5,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2018-0298","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,5,1]]},"published":{"date-parts":[[2018,11,8]]}}}